Maan R, Zaim R, van der Meer AJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Hansen BE, Janssen H, Veldt BJ, de Knegt RJ, Uyl-de Groot CA. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016;31:1851-9. [PMID: 26990109 DOI: 10.1111/jgh.13373][Cited by in Crossref: 2][Cited by in F6Publishing: 3][Article Influence: 0.4][Reference Citation Analysis]
Number
Citing Articles
1
Szymanek-Pasternak A, Simon KA, Serafińska S, Janocha-Litwin J, Pazgan-Simon M, Madej G. The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin. Clin Exp Hepatol 2016;2:155-60. [PMID: 28856281 DOI: 10.5114/ceh.2016.63873][Cited by in Crossref: 3][Cited by in F6Publishing: 3][Article Influence: 0.5][Reference Citation Analysis]
Perazzo H, Jorge MJ, Silva JC, Avellar AM, Silva PS, Romero C, Veloso VG, Mujica-Mota R, Anderson R, Hyde C, Castro R. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC Gastroenterol 2017;17:119. [PMID: 29169329 DOI: 10.1186/s12876-017-0676-8][Cited by in Crossref: 5][Cited by in F6Publishing: 4][Article Influence: 1.0][Reference Citation Analysis]
